trending Market Intelligence /marketintelligence/en/news-insights/trending/xQpxHx9ojknlM5JbtZki3Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Acceleron halts development of kidney cancer drug amid 'disappointing' results

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Acceleron halts development of kidney cancer drug amid 'disappointing' results

Acceleron Pharma Inc. said the phase 2 trial of dalantercept plus axitinib to treat advanced renal cell carcinoma, or RCC, a form of kidney cancer, did not achieve its primary endpoint.

Acceleron is disappointed by the results and will discontinue the development of dalantercept based on the lack of efficacy, said President and CEO Habib Dable.

The company had aimed for the study's primary efficacy endpoint to show a statistically significant increase in progression-free survival for dalantercept plus axitinib compared to placebo plus axitinib in advanced RCC patients.

Median progression-free survival for dalantercept plus axitinib was 6.8 months compared to 5.6 months for placebo plus axitinib. Dalantercept plus axitinib did not decrease the rate of disease progression or death.

The key secondary endpoint of the study was progression-free survival for patients who received two or more prior systemic anti-cancer therapies. In this evaluation, the median progression-free survival for dalantercept plus axitinib was 8.1 months versus 7.0 months for placebo plus axitinib. The confirmed objective response rate for dalantercept plus axitinib was 19% versus 25% for placebo plus axitinib.